新版《国家基本药物目录管理办法》发布

Core Viewpoint - The newly revised "National Basic Drug Directory Management Measures" aims to enhance the national basic drug system, ensuring the availability and accessibility of essential medications for public health needs, marking the first comprehensive update since 2015 [1] Group 1: Overview of the New Measures - The revision includes improvements in legal policy basis, directory structure optimization, management mechanism enhancement, emphasis on clinical value of drugs, standardization of dynamic adjustment mechanisms, and strengthening of monitoring and evaluation [1] - The core of the basic drug system is to select an appropriate number of essential drug varieties to meet the basic medication needs for disease prevention and treatment [1] Group 2: Selection and Adjustment of Basic Drugs - The dynamic adjustment of the basic drug directory will be based on clinical application practices, changes in drug standards, and the introduction of new drugs, adhering to principles such as prioritizing essential drugs and ensuring quality [2] - The basic drug directory will include chemical drugs, biological products, and traditional Chinese medicine, with special provisions for pediatric medications [2] Group 3: Focus on Pediatric Medications and Healthcare System Integration - The new measures incorporate pediatric medications into the basic drug management framework, addressing the specific needs of children [3] - Medical institutions are no longer required to stock all basic drugs, allowing for a more flexible approach in primary healthcare settings, which can now include some non-basic drugs to facilitate better integration with higher-tier hospitals [3] Group 4: Monitoring and Evaluation Framework - The National Health Commission will enhance the monitoring and clinical evaluation system focused on basic drugs, providing evidence and technical support for the dynamic optimization of the basic drug directory [4] - There will be a commitment to ensure that the selection process is transparent and that evaluation standards are scientific and evidence-based, allowing for timely inclusion of essential and cost-effective drugs [3][4]